This phase 2 randomized clinical trial compare the efficacy and toxicity profiles of durvalumab monotherapy and tremelimumab monotherapy against a combination of both in patients with recurrent or metastatic head and neck squamous cell carcinoma with low or no expression of programmed death ligand 1.
https://ift.tt/2Px4C2u
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου